Enanta Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Enanta Pharmaceuticals's earnings have been declining at an average annual rate of -57.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 26.3% per year.

Key information

-57.8%

Earnings growth rate

-57.6%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	-26.3%
Return on equity	-72.0%
Net Margin	-187.8%
Next Earnings Update	06 May 2024

Recent past performance updates

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25

Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11

Enanta Pharma is up after J.P. Morgan upgrade

Jan 29

Revenue & Expenses Breakdown
Beta

How Enanta Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ENTA Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	74	-138	57	159
30 Sep 23	79	-134	53	164
30 Jun 23	81	-132	52	162
31 Mar 23	81	-125	52	158
31 Dec 22	82	-121	49	157
30 Sep 22	86	-122	45	165
30 Jun 22	89	-120	41	179
31 Mar 22	92	-112	37	187
31 Dec 21	93	-101	35	186
30 Sep 21	97	-79	33	174
30 Jun 21	97	-84	31	162
31 Mar 21	94	-74	29	150
31 Dec 20	102	-58	28	141
30 Sep 20	122	-36	27	137
30 Jun 20	150	2	27	139
31 Mar 20	176	24	26	139
31 Dec 19	188	34	26	140
30 Sep 19	205	46	26	142
30 Jun 19	221	65	26	130
31 Mar 19	234	78	26	124
31 Dec 18	238	86	25	112
30 Sep 18	207	72	23	95
30 Jun 18	215	81	23	84
31 Mar 18	166	52	22	71
31 Dec 17	131	34	22	63
30 Sep 17	103	18	21	57
30 Jun 17	40	-21	20	52
31 Mar 17	46	-13	19	48
31 Dec 16	50	-10	18	44
30 Sep 16	88	22	17	40
30 Jun 16	90	29	16	36
31 Mar 16	87	33	16	31
31 Dec 15	132	63	15	28
30 Sep 15	161	79	14	23
30 Jun 15	149	68	13	21
31 Mar 15	180	116	12	20
31 Dec 14	124	82	11	19
30 Sep 14	48	34	10	19
30 Jun 14	46	35	9	18
31 Mar 14	6	-19	8	17
31 Dec 13	5	-19	7	16
30 Sep 13	32	-7	6	17
30 Jun 13	33	-3	6	17

Quality Earnings: ENTA is currently unprofitable.

Growing Profit Margin: ENTA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ENTA is unprofitable, and losses have increased over the past 5 years at a rate of 57.8% per year.

Accelerating Growth: Unable to compare ENTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ENTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).

Return on Equity

High ROE: ENTA has a negative Return on Equity (-72.04%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Enanta Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to US$21.38

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

New minor risk - Share price stability

Price target decreased by 11% to US$24.38

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Consensus revenue estimates fall by 25%

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Consensus estimates of losses per share improve by 18%

Price target decreased by 15% to US$57.40

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Senior VP exercised options to buy US$245k worth of stock.

President notifies of intention to sell stock

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates fall by 34%

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

President exercised options and sold US$919k worth of stock

Consensus revenue estimates fall by 10%

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta starts mid-stage trial of EDP-938 for RSV infection

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Price target increased to US$77.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Enanta Pharma FQ3 2022 Earnings Preview

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Price target decreased to US$69.80

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta: Slow Drip

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Enanta Pharmaceuticals, Inc. to Report Q1, 2022 Results on Feb 08, 2022

Senior VP & Chief Medical Officer exercised options and sold US$556k worth of stock

Revenue & Expenses Breakdown
Beta